Strides Arcolab stock: Growing portfolio to bear fruit in foreign markets

The stock of Strides Arcolab gained about 8 per cent this week on product approvals. This, coupled with its growing product portfolio, should meaningfully reflect on the US sales. Steady growth in Australian market and its branded generics in the rest of the world are the key triggers for the stock, which was an underperformer (down 37 per cent) over the last year.
 
The immediate trigger is the approval for the company’s products in the US market, where it is trying to build a base. The company has received an approval for a generic version of the HIV drug